Clinical Trials Browser

Head and Neck Neoplasms × Radiotherapy × 90 days × Clear all

NCT01647555 2026-03-18

Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer

Head and Neck Neoplasms

NCT01612351 2026-03-17

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Phase 2 Completed

40 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT03875716 2026-03-13

Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma

Phase NA Recruiting

Head and Neck Neoplasms

NCT04075305 2026-03-05

MOMENTUM

BreastCNSGastrointestinalGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Genital Neoplasms, Female, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Radiation Injuries, Rectal Neoplasms

NCT06208826 2026-03-03

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

Phase 2 Recruiting

Head and Neck Neoplasms

NCT05962242 2026-02-05

HN001

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03040999 2026-02-04

KEYNOTE-412

Phase 3 Completed

804 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06998069 2025-12-30

Head and Neck Cancer Study Project in the Geriatric Population

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07040969 2025-12-30

Spirulina-Derived Product Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors

Phase 2 Recruiting

Head and Neck Neoplasms

NCT06494189 2025-12-29

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

Phase 1 Completed

Head and Neck Neoplasms